Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO

  • Immuneering Corp IMRX has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as CFO earlier this year. 
  • Now, the biotech is hopping onto NASDAQ with a $112.5 million IPO. At the beginning of this month, the Company penciled in a $100 million IPO raise.
  • Immuneering offered 7.5 million shares at $15 apiece, the midpoint of a $14 to $16 range. 
  • Between $33 million and $38 million will be used to bring Immuneering’s lead candidate, a dual-MEK inhibitor dubbed IMM-1-104, into the clinic for advanced solid tumors in patients harboring RAS mutations, according to the S-1/A
  • Immuneering plans on submitting an IND for that candidate in the first quarter of 2022.
  • Another $38 million to $43 million will fund the development of other candidates in oncology and neuroscience.
  • Price Action: IMRX opened for trade at $19.50 and traded at $17.63 during the market session on the last check Friday.

Posted In: BriefsBiotechNewsHealth CareFinancingOfferingsIPOsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.